Company Overview
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company dedicated to developing the Lungfit platform, which functions as a nitric oxide generator and delivery system platform. The company executes its business strategy through three distinct segments: Beyond Air, Beyond Cancer, and NeuroNos, with a specific focus on offering Lungfit PH for the treatment of respiratory conditions. This entity functions within the Healthcare sector and the Medical Devices industry, positioning itself as a specialized developer of therapeutic technologies rather than a broad-line manufacturer. The company's current scale is defined by a market capitalization of $7.61M, annual revenue of $6.92M, and an employee base of 61. These financial dimensions indicate that Beyond Air, Inc. remains a small-cap enterprise with limited operational footprint relative to the broader medical device market, suggesting a position that relies heavily on successful product adoption and potential future capital allocation rather than established market dominance.
Financial Health
Beyond Air, Inc. reported revenue of $6.92M over the trailing twelve months, yet this top-line activity resulted in a net income of -$31,001,000 and an EBITDA of -$25,785,000. The significant gap between the $6.92M revenue and the -$31,001,000 net income reveals a cost structure characterized by substantial operating expenses that exceed gross profits, a common characteristic in the development phase of medical device companies. The free cash flow stands at -$18,648,376, indicating that the company is consuming cash to fund its operations and development efforts, which limits immediate financial flexibility for large-scale expansion without external financing. When analyzing profitability margins, the gross margin is 1.8%, the operating margin is -300.6%, and the profit margin is 0.0%, reflecting that the company is currently unprofitable across all standard metrics due to high fixed costs and R&D expenditures. On the balance sheet, the company holds $11.66M in cash against total debt of $23.59M, resulting in a debt-to-equity ratio of 284.71, which signifies a highly leveraged financial position where liabilities significantly outweigh equity. Despite the high debt load, the current ratio of 5.12 indicates strong short-term liquidity, suggesting the company possesses ample current assets to cover its short-term obligations. Finally, the return on equity is -240.2% and the return on assets is -51.2%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a typical but risky profile for a pre-revenue or early-revenue biopharmaceutical firm.
Valuation Assessment
The valuation of Beyond Air, Inc. presents a complex picture given its negative earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.44. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing the stock based on anticipated future earnings rather than historical profitability, reflecting high uncertainty regarding the trajectory of earnings. The price-to-book ratio is 0.75, indicating that the market values the company at less than its book value, which often suggests a market skepticism regarding the fair value of its intangible assets or future growth potential. Alternative valuation metrics such as the price-to-sales ratio of 1.10 and an EV/EBITDA of -0.76 provide further context, suggesting that investors are valuing the firm primarily on its revenue generation capacity despite the lack of positive cash flow from operations. The stock has experienced significant volatility, trading between a 52-week high of $6.40 and a 52-week low of $0.67. While the specific current price is not explicitly defined in the provided data, the wide range between these high and low points demonstrates substantial price movement over the past year. The beta value is 0.42, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting that the stock is less sensitive to general market fluctuations despite its high debt load and negative earnings profile.
Growth & Income
Beyond Air, Inc. demonstrated a revenue growth rate of 104.7% year-over-year, while earnings growth is N/A due to the company's negative earnings position. The absence of positive earnings growth means that revenue expansion is not yet translating into profitability, implying that the company is still in a phase where revenue scaling must precede operational leverage. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that it does not distribute earnings to shareholders and instead retains all capital for reinvestment. This reinvestment strategy is typical for small-cap medical device companies that prioritize funding research and development over providing income to investors. Consequently, the overall growth and income profile is defined by rapid top-line expansion coupled with a complete lack of current profitability or dividend income, positioning the stock as a pure-play growth vehicle with significant financial risk.